SPECTRUM

Sohrab P. Shah

Ignacio Vázquez-García

Andrew McPherson

Kevin M. Boehm

Resident physician working on machine learning for oncology

Florian Uhlitz

Dmitriy Zamarin

I am a Professor in Medical Oncology at Icahn School of Medicine at Mount Sinai (ISMMS) where I serve as the Section Head of Gynecologic Medical Oncology. I obtained my MD and PhD degrees from the Mount Sinai School of Medicine in New York where my research was focused on cellular responses to influenza viral infection and interactions of the influenza virus with the host immune system. I completed residency in Internal Medicine at the Mount Sinai Hospital in New York and fellowship in Hematology/Oncology at MSK, where I studied the mechanisms of response and resistance to immunomodulatory antibody therapy and oncolytic virus-based therapeutics. From 2014 to 2023 I was a faculty on the Gynecologic Medical Oncology service at MSK, where I served as the Translational Research Director. In August 2023 I joined ISMMS as the Section Head of Gynecologic Medical Oncology. My clinical practice and my clinical and laboratory research are focused on diagnosis and treatment of gynecologic cancers. In line with this work, I serve as the Translational co-Chair on the NRG Oncology Cervical Cancer Committee and a member of the NCI GCSC Ovarian Cancer Task Force. Since my academic appointment I have served as a clinical and translational PI on multiple investigator-sponsored and NCI-sponsored immunotherapy clinical trials in gynecologic cancers. In the laboratory, my research focuses on understanding of mechanisms of immune recognition in gynecologic cancers and on development of novel immunotherapeutics. My work has been funded by several agencies, including the Damon Runyon Cancer Research Foundation, Ovarian Cancer Research Alliance, National Cancer Institute, and Department of Defense.

Ovarian cancer mutational processes drive site-specific immune evasion

High-grade serous ovarian cancer is a genomically complex malignancy. Here the authors integrate whole-genome sequencing, single-cell RNA sequencing, digital histopathology and multiplexed immunofluorescence across 160 tumour sites from 42 patients, revealing that mutational processes shape site-specific immune evasion.

Ongoing genome doubling shapes evolvability and immunity in ovarian cancer

Single-cell whole-genome sequencing of 30,260 tumour genomes from 70 samples across 41 patients in the SPECTRUM cohort reveals that ongoing whole-genome doubling drives tumour evolvability and immune evasion in high-grade serous ovarian cancer.

Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer

Integration of genomic, histopathology, radiomics and clinical data using machine learning improves risk stratification for 444 patients with high-grade serous ovarian cancer.